Amneal Pharmaceuticals, Inc. filings document the regulatory record for a pharmaceutical issuer with Affordable Medicines, Specialty and AvKARE operations. The company’s 8-K reports cover operating and financial results, Regulation FD communications, clinical or regulatory disclosures, material agreements and capital-structure matters, including amendments to term loan credit arrangements involving Amneal Pharmaceuticals LLC and subsidiary guarantors.
Amneal’s proxy and annual-meeting filings describe board elections, advisory executive-compensation votes, auditor ratification and other stockholder voting matters. Its material-event disclosures also record governance matters, shareholder votes, opioids-related settlement obligations, and financial-statement exhibits tied to press releases and other public-company reporting.
Charles Schwab Corp filed a notice of proposed sale of 2,917,998 shares of its common stock under Rule 144. The filing lists prior equity compensation grants in the form of Restricted Stock Awards from 2017 through 2025, with individual grants ranging from a few thousand to over 76,000 shares. The issuer reports 319,353,919 common shares outstanding in connection with this planned resale.
Amneal Pharmaceuticals, Inc. completed the acquisition of Kashiv BioSciences, LLC, purchasing 100% of Kashiv’s membership interests through its wholly owned subsidiary Amneal Pharmaceuticals LLC. The consideration at closing included $375,000,000 in cash, subject to purchase price adjustments, and the issuance of 28,942,098 shares of Class A common stock as stock consideration to the sellers.
Under the purchase agreement, the sellers may receive up to an additional $350,000,000 in contingent payments tied to specified U.S. regulatory milestones for up to six Kashiv product candidates, plus potential contingent royalty payments over 12 years equal to 25% of certain annual gross profits above defined hurdles. To help fund the transaction, Amneal LLC entered into an amendment to its term loan credit agreement, under which Bank of America, N.A. provided a $350,000,000 incremental term loan.
Amneal amended its Stockholders Agreement to ensure the new stock consideration is counted in Amneal Group ownership calculations and relied on a private-offering exemption to issue the shares to accredited investors. The company plans to file an S-3 registration statement to permit public resale of the stock consideration and will later provide Kashiv’s financial statements and pro forma financial information.
Amneal Pharmaceuticals reported solid results for the three and six months ended June 30, 2026. Net revenue was $796,197 (in thousands) in Q2 2026 versus $724,508 (in thousands) a year earlier, and net income attributable to Amneal was $57,662 (in thousands) versus $22,417 (in thousands). For the first half, net revenue reached $1,518,716 (in thousands) and net income attributable to Amneal was $119,918 (in thousands). Diluted EPS was $0.18 in Q2 and $0.37 year-to-date. A very low effective tax rate of 1.9% in Q2 and 2.3% year-to-date supported bottom-line growth.
At June 30, 2026, Amneal held cash, cash equivalents and restricted cash of $139,619 (in thousands) and total assets of $3,776,348 (in thousands). Total debt was $2,684,263 (in thousands), primarily a Term Loan and Senior Notes due 2032, with interest expense, net of $108,404 (in thousands) for the first half. Operating cash flow swung to an outflow of $47,987 (in thousands), reflecting higher receivables, inventory builds and significant product-rights investments.
Strategically, Amneal is expanding through agreements including a $75,000 (in thousands) upfront payment to MSN for U.S. mirabegron rights, new tirzepatide and denosumab biosimilar arrangements, and a definitive deal to acquire Kashiv BioSciences for $375,000 (in thousands) in cash plus 28,942,108 shares and up to $350,000 (in thousands) in milestones and profit-based royalties. Legally, a Nationwide Opioids Settlement Agreement became effective, with total expected cash payments of $133.5 million through 2034 and naloxone product deliveries, and a $9,000 (in thousands) accrual was recorded for antitrust class action litigation.
Amneal Pharmaceuticals, Inc., through subsidiary Amneal Pharmaceuticals LLC, entered into Amendment No. 3 to its Term Loan Credit Agreement, converting on a cashless basis existing term loans into new term loans with an aggregate principal amount of $2.039 billion and incurring an additional $45.2 million term loan used to prepay at par remaining existing loans.
The amendment reduces the interest rate margin on these Amendment No. 3 Term Loans by 50 basis points to 1.50% for base rate loans and 2.50% for loans based on the secured overnight financing rate, while keeping the stated maturity at August 1, 2032. It also permits a future repricing transaction without a prepayment premium if it occurs after February 3, 2027. The company estimates annualized cash interest expense savings of approximately $12 million compared with the prior credit agreement, based on amounts outstanding immediately before the amendment.
Amneal Pharmaceuticals, Inc. reported that stockholders at a July 31, 2026 special meeting approved the Transaction Proposal to enter into the Membership Interest Purchase Agreement and acquire 100% of the issued and outstanding membership interests of Kashiv BioSciences, LLC. Disinterested stockholders cast 138,265,079 votes for, 655,759 against and 67,147 abstaining, satisfying the required approval condition.
Stockholders also approved the Stock Issuance Proposal to issue 28,942,108 shares of Class A common stock to the Kashiv sellers for Nasdaq Listing Rule 5635(a)(2) compliance, with 286,714,072 votes for, 1,791,016 against and 62,071 abstentions. Of 319,331,346 shares outstanding on the June 25, 2026 record date, 288,567,159 were represented, constituting a quorum. Closing of the Kashiv transaction is expected in the second half of 2026, assuming all remaining conditions and required regulatory approvals are satisfied.
Amneal Pharmaceuticals reported Q2 2026 net revenue of $796 million, up 10% from $725 million a year earlier. Net income attributable to Amneal was $58 million, with diluted EPS of $0.18. Adjusted EBITDA was $206 million and adjusted diluted EPS $0.30, both higher than Q2 2025.
Specialty net revenue grew 17%, Affordable Medicines rose 13%, while AvKARE declined 4%. For the first half of 2026, net cash (used in) provided by operating activities was $(47,987) thousand versus $91,227 thousand provided in the prior-year period.
The company repriced its $2.084 billion Term Loan B, cutting the rate by 50 bps to SOFR plus 250 bps, expected to save about $12 million in annual cash interest, and plans an additional $350 million Term Loan B to help fund the pending Kashiv BioSciences acquisition. 2026 guidance was raised: net revenue to $3.10–$3.20 billion, adjusted EBITDA to $750–$780 million, and adjusted diluted EPS to $0.96–$1.06. Net debt was $2.66 billion with non-GAAP net leverage of 3.6x for the last twelve months ended June 30, 2026.
Amneal Pharmaceuticals is asking stockholders to approve its acquisition of 100% of Kashiv BioSciences’ membership interests pursuant to a Membership Interest Purchase Agreement. At closing Amneal will pay $375,000,000 in cash and issue 28,942,108 shares of Class A common stock to the sellers. The sellers may receive up to $350,000,000 in contingent cash payments tied to U.S. regulatory milestones and potential royalty payments equal to 25% of annual aggregate gross profits above specified hurdles for up to 12 years. The transaction is conditioned on stockholder approvals (the transaction proposal and the stock issuance proposal), HSR Act clearance, certain Indian regulatory approvals and other closing conditions. The Independent Committee and the Amneal Board each unanimously recommend a vote FOR all proposals.
The special meeting will be held online on July 31, 2026. The record date for voting was June 25, 2026, and Amneal had 319,331,346 shares outstanding as of that date. Completion of the Transaction requires both the transaction approval (by Amneal disinterested stockholders) and the stock issuance approval; either failure will prevent closing.
Amneal Pharmaceuticals is seeking shareholder approval to acquire 100% of Kashiv BioSciences under a Membership Interest Purchase Agreement dated April 21, 2026. Consideration at closing includes $375,000,000 in cash and 28,942,108 shares of Amneal Class A common stock, with up to $350,000,000 of contingent cash and potential royalty payments equal to 25% of certain excess gross profits for up to 12 years. The Board and the Independent (Conflicts) Committee unanimously recommend voting FOR (transaction approval, stock issuance and an adjournment proposal). The transaction is conditioned on disinterested stockholder approval, Nasdaq shareholder approval for the share issuance, HSR clearance and certain Indian regulatory approvals, and is expected to close in the second half of 2026.
Amneal Pharmaceuticals director Deborah M. Autor reported an open-market sale of Class A Common Stock. On May 11, 2026, she sold 34,819 shares at a weighted average price of $12.94 per share in multiple trades between $12.75 and $13.27. Following the sale, she directly holds 93,660 shares.